Evaro raises £18.3M Series A for NHS-licensed digital prescription app — full details
What Evaro does
Evaro provides an NHS-licensed “healthcare-as-a-service” platform that allows companies and healthcare providers to integrate regulated medical services directly into their apps or websites. (UKTN)
Core capabilities include:
- Digital consultations reviewed by UK-registered clinicians
- Remote diagnosis and treatment for common conditions
- Prescription generation and dispensing
- Medication delivery to patients’ homes
- Aftercare and follow-up support (Evaro)
The company holds regulatory approvals from:
- NHS pharmacy licence
- Care Quality Commission (CQC)
- General Pharmaceutical Council (GPhC) (Startup Researcher)
These licences enable partners to legally offer prescription care without building medical infrastructure themselves.
The problem it solves
The startup targets pressure on the UK healthcare system, where many patients wait days or weeks for GP appointments.
Evaro’s founders created the platform to treat routine medical issues digitally, improving access while reducing burden on doctors. (Startup Researcher)
Through integrations such as the Patchs platform, patients can:
- complete an AI-supported questionnaire,
- have a clinician review it,
- receive medication the next day if approved. (Evaro)
The service can handle many common conditions (e.g., UTIs, sore throat, sinusitis, shingles and minor infections). (Evaro)
Business model: “embedded healthcare”
Evaro’s main innovation is turning healthcare into an infrastructure layer similar to embedded payments or banking.
Companies — including consumer apps and retailers — can add medical services directly into their customer journeys. (Startup Researcher)
Target customers:
- Consumer brands creating new revenue streams
- Healthcare providers expanding digital capacity
- Employers offering staff health benefits (UKTN)
The platform already supports 80+ conditions and millions of patients. (Startup Researcher)
How the funding will be used
The Series A investment will help Evaro:
- Scale infrastructure across the UK
- Expand partnerships with consumer brands
- Increase treatment coverage
- Improve NHS access efficiency
- Grow the embedded healthcare category (UKTN)
The company aims to make healthcare “as accessible as online banking” by enabling instant treatment for routine conditions. (UKTN)
Why it matters
Evaro represents a broader shift toward API-based healthcare delivery, where care happens inside everyday apps rather than hospitals.
Potential impact:
- Faster patient treatment
- Reduced GP workload
- New revenue models for brands
- Hybrid public-private healthcare infrastructure
In short: Evaro is trying to become the Stripe-style infrastructure layer for digital healthcare — embedding prescriptions wherever users already interact online.
Evaro raises £18.3M Series A for NHS-licensed digital prescription app — case studies and comments
Real-world case studies
1) Embedding prescriptions inside consumer apps (Clue & Lovehoney)
Evaro’s core model is “healthcare-as-a-service” — brands plug clinical care directly into their existing customer journeys instead of sending users to external clinics.
How it works
- User answers an asynchronous questionnaire
- Clinician reviews responses
- Prescription issued digitally
- Medication dispensed and delivered
Partners like the period-tracking app Clue and retailer Lovehoney integrate treatment access into their platforms. (EU-Startups)
Impact
- Healthcare becomes part of normal digital behaviour (shopping, tracking health)
- Higher treatment adherence (patients already engaged in app)
- New revenue streams for partner brands
This shows a major shift: healthcare moving from hospitals → platforms.
2) NHS pressure reduction via Pharmacy-First style access
Evaro’s system supports remote treatment for common conditions and eliminates GP appointments for routine care.
Examples include:
- UTIs
- Skin conditions
- Respiratory infections
- Menopause and erectile dysfunction treatments (Evaro)
Measured outcome
- Over 350,000 patients served
- Nearly £11M saved for the NHS (agilebusiness.org)
Why it matters
Primary care systems globally face doctor shortages — digital prescribing removes unnecessary appointments.
3) Scaling integrated digital care to millions
The company already supports 2+ million patients and plans to reach 10 million within three years. (Evaro)
The Series A funding will expand:
- Women’s health
- Men’s health
- Longevity medicine
- Diagnostics and aftercare (EU-Startups)
This demonstrates a move toward “continuous healthcare” instead of episodic visits.
Industry significance
Embedded healthcare becomes a platform feature
Evaro enables any consumer company to offer regulated medical treatment.
Old model:
Healthcare provider owns patient relationship
New model:
Platform owns experience, clinicians operate in background
This is similar to fintech APIs — but applied to medicine.
Asynchronous care replaces appointments
No video calls required — consultations occur via structured questionnaires. (agilebusiness.org)
This:
- Cuts clinician workload
- Speeds treatment
- Expands access in underserved areas
Pharmacy + e-commerce convergence
Prescription fulfilment and logistics operate like online retail:
- automated
- delivered
- subscription-based
Healthcare is becoming operationally similar to Amazon.
Comments & analysis
Why investors funded it
The startup sits at the intersection of three massive trends:
- Telehealth adoption after COVID
- NHS capacity crisis
- Platform economy (APIs everywhere)
Instead of competing with hospitals, Evaro turns every app into a clinic.
The disruptive insight
Telemedicine 1.0 = video consultations
Telemedicine 2.0 = invisible healthcare infrastructure
Patients don’t “go to the doctor”
→ care appears inside apps they already use.
Potential benefits
- Faster treatment access
- Reduced hospital congestion
- Lower healthcare costs
- Continuous preventive care
Potential concerns
- Over-prescription risk if poorly regulated
- Data privacy responsibilities shift to consumer brands
- Loss of traditional GP relationship continuity
Strategic takeaway
Evaro isn’t really a telehealth company.
It’s:
Stripe for prescriptions
The business model could fundamentally reshape healthcare delivery — turning regulated medicine into an embedded digital service rather than a physical location.